<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056004</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271915</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2405</secondary_id>
    <secondary_id>WSU-093201MP4F</secondary_id>
    <nct_id>NCT00056004</nct_id>
  </id_info>
  <brief_title>Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia</brief_title>
  <official_title>Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of zileuton may be an effective way to prevent&#xD;
      lung cancer in patients who have bronchial dysplasia.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of zileuton in preventing lung&#xD;
      cancer in patients who have bronchial dysplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of zileuton, in terms of number of sites and grade of dysplastic&#xD;
           lesions in the bronchial epithelium, in patients with documented bronchial dysplasia.&#xD;
&#xD;
        -  Correlate the regression of bronchial dysplasia (number and grade) and improvement in&#xD;
           sputum cytology with the modulation of molecular biomarkers in patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the overall toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the 6-month natural history of bronchial dysplasia in patients who are&#xD;
           randomized to receive treatment with a placebo.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified according to smoking status (current vs recently quit smoker), and prior cancer&#xD;
      (none vs lung or head and neck). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral zileuton 4 times daily for 6 months in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo 4 times daily for 6 months in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 134 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchial dysplasia number and grade at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (Ki-67, Cyclin D1, bcl-2, bax, caspase-3) by immunohistochemistry at 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (5-HETE, LTB-4) by blood and BAL levels at 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as measured by number and severity monthly</measure>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At high risk for dysplasia, defined by 1 of the following criteria:&#xD;
&#xD;
               -  Current or former smokers who have smoked at least 30 pack-years&#xD;
&#xD;
                    -  Former smokers must be enrolled within 20 years of complete smoking&#xD;
                       cessation&#xD;
&#xD;
               -  Patients with curatively treated stage I non-small cell lung cancer*&#xD;
&#xD;
               -  Patients with curatively treated stage I or II squamous cell carcinoma of the&#xD;
                  head and neck (limited to oral cavity, pharynx, or larynx)* NOTE: *At least 12&#xD;
                  months post-curative therapy&#xD;
&#xD;
          -  Histologic confirmation of mild to severe bronchial dysplasia on bronchoscopic biopsy&#xD;
             required&#xD;
&#xD;
               -  Moderate or severe atypia on sputum cytology required before bronchoscopy (not&#xD;
                  required for patients with prior lung or head and neck cancer)&#xD;
&#xD;
          -  No evidence of malignancy by chest x-ray&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over (for patients with prior lung or head and neck malignancy)&#xD;
&#xD;
          -  35 and over (for all other patients)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  Liver enzymes no greater than ULN&#xD;
&#xD;
          -  PT/PTT no greater than ULN&#xD;
&#xD;
          -  No active or chronic liver disease (even if transaminases have normalized)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No significant asthma or chronic obstructive pulmonary disease requiring chronic or&#xD;
             periodic (at least once per year) steroids for flares&#xD;
&#xD;
          -  No acute or chronic respiratory failure&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing and able to undergo serial bronchoscopic examinations&#xD;
&#xD;
          -  No ongoing alcohol use (i.e., at least 1 glass of wine, beer, or a mixed drink per day&#xD;
             on a regular basis)&#xD;
&#xD;
          -  No other medical condition that would preclude safety during study participation&#xD;
&#xD;
          -  No other active or invasive malignancy within the past 5 years except basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No hypersensitivity to study drug or any of its inactive ingredients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 3 months since prior corticosteroids*&#xD;
&#xD;
          -  No concurrent corticosteroids*&#xD;
&#xD;
          -  No concurrent anticancer hormonal agents NOTE: *Systemic or inhaled, including chronic&#xD;
             administration&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior lipoxygenase inhibitors*&#xD;
&#xD;
          -  More than 3 months since prior investigational agents&#xD;
&#xD;
          -  More than 3 months since prior nutritional supplements (except 1 daily multivitamin)&#xD;
&#xD;
          -  No concurrent nutritional supplements (except 1 daily multivitamin)&#xD;
&#xD;
          -  No other concurrent lipoxygenase inhibitors*&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent warfarin, beta-blockers, or theophylline&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  No concurrent or chronic daily use of non-steroidal anti-inflammatory agents (NSAIDS)&#xD;
             (except cardioprotective doses of aspirin less than 100 mg/day)&#xD;
&#xD;
               -  Periodic use of NSAIDS allowed&#xD;
&#xD;
          -  Concurrent participation in a smoking cessation program (including use of bupropion or&#xD;
             nicotine gum or patch) allowed NOTE: *Systemic or inhaled, including chronic&#xD;
             administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Kucuk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zileuton</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

